Skip to main content

Table 1 Summary of health care system expenditure, by country 2013, £ million and % of total

From: The economic impact of sight loss and blindness in the UK adult population

 

England

Wales

Scotland

Northern Ireland

UK

Hospital recurrent expenditure

588.9, 23.9%

44.7, 29.6%

85.9, 29.4%

15.3, 19.1%

734.9, 24.6%

Non-admitted expenditure

673.8, 27.3%

33.7, 22.3%

47.3, 16.2%

16.3, 20.3%

771.1, 25.8%

 Prescribing expenditure

137.9, 5.6%

9.0, 6.0%

11.8, 4.0%

3.9, 4.9%

162.6, 5.4%

 Ranibizumab (Lucentis)a

184.0, 7.5%

11.6, 7.7%

17.5, 6.0%

5.2, 6.5%

218.3, 7.3%

General ophthalmic services (GOS)

481.1, 19.5%

32.3, 21.4%

80.9, 27.7%

20.2, 25.2%

614.6, 20.6%

Expenditure associated with injurious falls

19.9, 0.8%

1.0, 0.7%

2.0, 0.7%

0.6, 0.7%

23.4, 0.8%

 

(16.2, 0.7% - 23.7, 1.0%)

(0.8, 0.5% - 1.2, 0.8%)

(1.6, 0.5% - 2.4, 0.8%)

(0.5, 0.6% - 0.7, 0.9%)

(19.1, 0.6% - 28.0, 0.9%)

Research and development

14.1, 0.6%

0.5, 0.3%

2.1, 0.7%

0.3, 0.4%

17.0, 0.6%

Residential care and community care services

220.8, 9.0%

13.2, 8.7%

31.7, 10.9%

11.0, 13.7%

276.8, 9.3%

Capital and administration

145.7, 5.9%

5.1, 3.4%

12.8, 4.4%

7.1, 8.9%

170.7, 5.7%

Total

2466.1

151.1

292.1

80.1

2989.3

 

(2462.4–2469.9)

(150.9–151.3)

(291.7–292.4)

(80.0–80.2)

(2985.0–2993.9)

  1. aRanibizumab (Lucentis) sales data for the UK has been split based on the estimates of prevalence for AMD